Nov 4 2020

CRISPR/Cas9 Gene-Editing Therapy CTX001™ for Severe Hemoglobinopathies Accepted for Plenary Presentation at the 62nd American Society of Hematology (ASH) Meeting and Exposition

CRISPR/Cas9 Gene-Editing Therapy CTX001™ for Severe Hemoglobinopathies Accepted for Plenary Presentation at the 62nd American Society of Hematology (ASH) Meeting and Exposition – Book Publishing Industry Today – EIN Presswire

Trusted News Since 1995

A service for publishing professionals
·
Wednesday, November 4, 2020

·
530,001,226
Articles

·
3+ Million Readers